Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Status:
Recruiting
Trial end date:
2028-02-28
Target enrollment:
Participant gender:
Summary
This study is a Phase 1multicenter study with a Dose Escalation and Dose Expansion evaluating
safety and efficacy of MT-601 administration to patients with Relapsed or Refractory NHL. The
dose administered is 200 x 10^6 cells (flat dosing).